ElevateBio raises $525 million in funding from SoftBank, others
ElevateBio raises $525 million in funding from SoftBank, others
By Manas Mishra
March 15 (Reuters) - ElevateBio said on Monday it has raised $525 million in new funding led by Matrix Capital Management, to help increase manufacturing capacity and also advance development of its cell and gene therapies.
The new financing, one of the bigger fund raises in the healthcare sector this year, also included investment from SoftBank Vision Fund 2, the cell and gene therapy developer said.
The company is the largest shareholder in cell therapy developer Allovir Inc ALVR.O , and its other portfolio companies include HighPassBio, which is also developing a treatment for leukemia patients.
ElevateBio is seeing demand for manufacturing services from both its portfolio companies, as well as from academic researchers and biotech companies, said co-founder and Chief Executive Officer David Hallal.
The funding comes as larger drugmakers work to build their own manufacturing plants for gene therapies, in a drive to better control production of the world&aposs priciest medicines.
Biogen Inc BIIB.O said earlier this month that it planned to spend $200 million to build a new gene therapy manufacturing facility.
"We do have a fundamental belief that a large percentage of innovation will keep coming through traditional academic or early-stage companies," Hallal said.
These companies, however, "don&apost necessarily have either the time, the capital or the talent, to accelerate their programs forward."
As part of the series C funding round, ElevateBio said Karan Takhar, senior managing director at Matrix Capital Management and Deep Nishar, senior managing partner, SoftBank Investment Advisers, will join its board of directors.
By Manas Mishra
马纳斯·米什拉(Manas Mishra)著
March 15 (Reuters) - ElevateBio said on Monday it has raised $525 million in new funding led by Matrix Capital Management, to help increase manufacturing capacity and also advance development of its cell and gene therapies.
路透3月15日电-ElevateBio周一表示,已从Matrix Capital Management牵头的新融资中筹集5.25亿美元,以帮助提高产能,并推进其细胞和基因疗法的开发.
The new financing, one of the bigger fund raises in the healthcare sector this year, also included investment from SoftBank Vision Fund 2, the cell and gene therapy developer said.
新的融资,一细胞和基因治疗开发商软银愿景基金2(SoftBank Vision Fund 2)表示,在今年医疗行业规模较大的融资中,还包括软银愿景基金2(SoftBank Vision Fund 2)的投资。
The company is the largest shareholder in cell therapy developer Allovir Inc ALVR.O , and its other portfolio companies include HighPassBio, which is also developing a treatment for leukemia patients.
该公司是细胞疗法开发商的最大股东。Allvir Inc.ALVR.O及其其他投资组合公司包括HighPassBio,后者也在开发一种治疗白血病患者的方法。
ElevateBio is seeing demand for manufacturing services from both its portfolio companies, as well as from academic researchers and biotech companies, said co-founder and Chief Executive Officer David Hallal.
ElevateBio联合创始人兼首席执行官大卫·哈拉尔(David Hallal)表示,ElevateBio看到其投资组合公司以及学术研究人员和生物技术公司对制造服务的需求。
The funding comes as larger drugmakers work to build their own manufacturing plants for gene therapies, in a drive to better control production of the world&aposs priciest medicines.
这笔资金出台之际,规模较大的制药商正努力建立自己的基因疗法制造工厂,以更好地控制世界上最昂贵的药物的生产。
Biogen Inc BIIB.O said earlier this month that it planned to spend $200 million to build a new gene therapy manufacturing facility.
生物遗传公司BIIB.O本月早些时候表示,计划斥资2亿美元建设一个新的基因疗法制造设施。
"We do have a fundamental belief that a large percentage of innovation will keep coming through traditional academic or early-stage companies," Hallal said.
哈拉尔说:“我们确实有一个基本信念,即很大比例的创新将继续来自传统的学术或初创公司。”
These companies, however, "don&apost necessarily have either the time, the capital or the talent, to accelerate their programs forward."
然而,这些公司“不一定有时间、资金或人才来加速他们的计划。”
As part of the series C funding round, ElevateBio said Karan Takhar, senior managing director at Matrix Capital Management and Deep Nishar, senior managing partner, SoftBank Investment Advisers, will join its board of directors.
作为C系列融资的一部分,ElevateBio表示,Matrix Capital Management高级董事总经理卡兰·塔哈尔(Karan Takhar)和软银投资顾问公司(SoftBank Investment Advisers)高级管理合伙人迪普·尼沙尔(Deep Nishar)将加入董事会。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧